Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03277456
Recruitment Status : Completed
First Posted : September 11, 2017
Last Update Posted : November 14, 2017
Sponsor:
Collaborator:
University of Oxford
Information provided by (Responsible Party):
Vaccitech (UK) Limited

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This is a first in human, phase I, open label study of the MVA viral vector (produced in the novel immortalised duck retinal cell line AGE1.CR.pIX) expressing the influenza antigens NP and M1 as a fusion protein, in healthy adult volunteers. MVA-NP+M1 will be given alone intramuscularly as a single dose.

There will be 1 study group and a total of 6 volunteers will be enrolled. Staggered enrollment will apply for the first three volunteers within the group.


Condition or disease Intervention/treatment Phase
Human Volunteers Biological: MVA-NP+M1 Early Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1, Manufactured on the AGE1.CR.pIX Novel Avian Cell Line, in Healthy Adult Volunteers.
Actual Study Start Date : September 18, 2017
Actual Primary Completion Date : November 2, 2017
Actual Study Completion Date : November 2, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot Vaccines

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Single intramuscular injection of MVA-NP+M1 vaccine
MVA-NP+M1, a novel vaccine will be administered intramuscular. The total volume given is 0.5ml and the dose given is 1.5E8 pfu. Each volunteer will receive one single injection only over a few seconds.
 Biological: MVA-NP+M1
Intramuscular injection of novel vaccine


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Measure of local reactogenicity following intramuscular injection of MVA-NP+M1 [ Time Frame: 7 days post vaccination ]
    Occurrence and severity of solicited local reactogenicity signs and symptoms for 7 days following vaccination using a diary card.

  2. Measure of systemic reactogenicity following intramuscular injection of MVA-NP+M1 [ Time Frame: 7 days post vaccination ]
    Occurrence and severity rating of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination using a diary card.

  3. Measure the occurrence of adverse events following intramuscular injection of MVA-NP+M1 [ Time Frame: 28 days post vaccination ]
    Occurrence and severity of unsolicited adverse events for 28 days following the vaccination using a diary card.

  4. Assessment of safety laboratory assessments following intramuscular injection of MVA-NP+M1 [ Time Frame: 28 days post vaccination ]
    Review of changes in safety laboratory measures from baseline visit to Day 2, Day 7, Day 21 and Day 28 visits

  5. Serious Adverse Events that occur during the study [ Time Frame: 28 days post vaccination ]
    Review of causality and relationship to MVA-NP+M1 for any serious adverse events during the whole study duration


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy adults aged 18-50
  2. Able and willing (in the Investigator's opinion) to comply with all study requirements
  3. Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner
  4. For females only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination (for women of child bearing potential only)
  5. Agreement to refrain from blood donation during the course of the study
  6. Provide written informed consent

Exclusion Criteria:

  1. Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
  2. Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data.
  3. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
  4. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
  5. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
  6. Any history of anaphylaxis in relation to vaccination
  7. Pregnancy, lactation or willingness/intention to become pregnant during the study (for women of child bearing potential only)
  8. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
  9. History of serious psychiatric condition likely to affect participation in the study
  10. Bleeding disorder (eg. Factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture
  11. Any other serious chronic illness requiring hospital specialist supervision
  12. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week
  13. Suspected or known injecting drug abuse in the 5 years preceding enrolment
  14. Seropositive for hepatitis B surface antigen (HBsAg)
  15. Seropositive for hepatitis C virus (antibodies to HCV)
  16. Any clinically significant abnormal finding on screening biochemistry and haematology blood tests or urinalysis
  17. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
  18. Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03277456


Locations
Layout table for location information
United Kingdom
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM)
Oxford, Oxfordshire, United Kingdom, OX3 7LJ
Sponsors and Collaborators
Vaccitech (UK) Limited
University of Oxford
Investigators
Layout table for investigator information
Principal Investigator: Adrian Hill, MD Director, The Jenner Institute, Oxford University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Vaccitech (UK) Limited
ClinicalTrials.gov Identifier: NCT03277456    
Other Study ID Numbers: FLU008
First Posted: September 11, 2017    Key Record Dates
Last Update Posted: November 14, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No